Imugene (ASX: IMU) welcomes cell therapy specialist Dr Bradley Glover as COO

August 21, 2023 11:17 AM AEST | By Sonal Goyal

Imugene (ASX: IMU) welcomes cell therapy specialist Dr Bradley Glover as COO — Image source: Company website

Recent News

Gold Resource Corporation Announces Management Changes

IBM Faces Investor Doubts Despite Beating Estimates

ASX Opens Higher Amid Hints of US Tariff Easing on China

ASX Opens Steady Amid Global Trade Tensions; Resource Exploration Gain...

Highlights

Imugene has announced the appointment of Dr Bradley Glover as its chief operating officer (COO).

Dr Glover carries experience in various sectors, including biopharmaceuticals and cell therapy.

He is expected to aid the company in advancing its technology pipeline, backed by his extensive expertise.

Imugene Limited (ASX: IMU) has made a new addition to its team with the appointment of Dr Bradley Glover as its chief operating officer.

Dr Glover, a cell therapy specialist, has a career spanning various sectors. He holds a doctorate degree in biochemistry & molecular genetics from the University of Colorado. He has published research articles in the same field. He completed MBA in marketing & finance from the Rady School of Management, University of California San Diego.

Data source: Company update

Rich industry experience of Dr Glover

Dr Glover has experience in various sectors, such as biopharmaceuticals, finance, venture capital, cell therapy, diagnostics, education, and research & development. He has shown expertise in licensing agreements, acquisitions, strategic collaborations, and deal negotiations.

Previously, Dr Glover was associated with Celularity as Executive Vice President and COO. At Celularity, he played a significant role in technical operations, business development and strategic planning.

He worked with renowned cell therapy company Kite Pharma as Vice President and Head of Corporate Strategy & Operations, where he was responsible for global business transformation, product and program management, portfolio management, global corporate strategy and planning.

He worked at Genentech / Roche for eight years, overseeing strategic planning, business integration and development. In his leadership roles at Genentech / Roche, he led the integration of Roche’s acquisitions for its diagnostics sequencing business, totalling approximately AU$1.2 billion.

IMU shares traded at AU$0.077 apiece at the time of writing on 21 August 2023.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.